Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.
We retrospectively evaluated the role of rituximab (R) in maintenance treatment after autologous stem cell transplantation performed in patients with relapsed follicular lymphoma. We compared the outcome of 67 follicular lymphoma (FL) patients according to the use of rituximab maintenance (RM) or not. All patients received rituximab plus chemotherapy before autologous stem-cell transplantation (ASCT). Patients received median of two lines of prior therapy. The RM schedule was one injection of rituximab every 3 months for 2 years. Median follow-up is 4.6 years. The 3-year progression-free survival (PFS) after ASCT was 86 % with RM vs. 46 % without (p = 0.0045). Median is not reached in the RM arm vs. 31 months in non-RM arm. The 3-year OS was 96 % with RM vs. 78 % without (p = 0.059). The present monocentric study shows that 2 years of RM after ASCT significantly increases response duration for non-naive rituximab relapsed FL patients compared with observation.
Department of Hematology, University Hospital of Nantes, Nantes, France.
J
J
Bourcier
Department of Hematology, University Hospital of Nantes, Nantes, France.
T
T
Gastinne
Department of Epidemiology, University Hospital of Nantes, Nantes, France.
C
C
Leux
Department of Pathology, University Hospital of Nantes, Nantes, France.
A
A
Moreau
Department of Pathology, University Hospital of Nantes, Nantes, France.
C
C
Bossard
Department of Hematology, University Hospital of Nantes, Nantes, France.
B
B
Mahé
Department of Hematology, University Hospital of Nantes, Nantes, France.
N
N
Blin
Department of Hematology, University Hospital of Nantes, Nantes, France.
V
V
Dubruille
Department of Hematology, University Hospital of Nantes, Nantes, France.
C
C
Touzeau
Department of Hematology, University Hospital of Nantes, Nantes, France.
M
M
Voldoire
Department of Hematology, University Hospital of Nantes, Nantes, France.
T
T
Guillaume
Department of Hematology, University Hospital of Nantes, Nantes, France.
P
P
Peterlin
Department of Hematology, University Hospital of Nantes, Nantes, France.
P
P
Gallas
Department of Hematology, University Hospital of Nantes, Nantes, France.
A
A
Garnier
Department of Hematology, CHD de la Roche-Sur-Yon, La Roche-sur-Yon, France.
H
H
Maisonneuve
Department of Hematology, CH de Lorient, Lorient, France.
P
P
Moreau
Centre Catherine de Sienne, Rezé, France.
N
N
Juge-Morineau
Department of Hematology, CH de Vannes, Vannes, France.
H
H
Jardel
Department of Hematology, University Hospital of Nantes, Nantes, France.
P
P
Chevallier
Department of Hematology, University Hospital of Nantes, Nantes, France.
P
P
Moreau
Department of Hematology, University Hospital of Nantes, Nantes, France. steven.legouill@chu-nantes.fr.|INSERM, UMR892, Equipe 10, Nantes, France. steven.legouill@chu-nantes.fr.|INSERM, CIC 004, Nantes University Hospital, Nantes, France. steven.legouill@chu-nantes.fr.
S
S
Le Gouill
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008224:Lymphoma, Follicular / Q000473:pathology / Q000628:therapy*; D060046:Maintenance Chemotherapy / Q000379:methods; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D017063:Outcome Assessment, Health Care / Q000379:methods* / Q000706:statistics & numerical data; D011184:Postoperative Period; D016016:Proportional Hazards Models; D012074:Remission Induction; D012189:Retrospective Studies; D000069283:Rituximab / Q000008:administration & dosage; D013997:Time Factors; D014182:Transplantation, Autologous; D055815:Young Adult
D000069283:Rituximab
Autologous stem cell transplantation; Follicular lymphoma; Relapse; Rituximab maintenance